HUE071358T2 - Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk - Google Patents

Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk

Info

Publication number
HUE071358T2
HUE071358T2 HUE17726487A HUE17726487A HUE071358T2 HU E071358 T2 HUE071358 T2 HU E071358T2 HU E17726487 A HUE17726487 A HU E17726487A HU E17726487 A HUE17726487 A HU E17726487A HU E071358 T2 HUE071358 T2 HU E071358T2
Authority
HU
Hungary
Prior art keywords
therapeutic agents
benzenesulfonamide compounds
benzenesulfonamide
compounds
therapeutic
Prior art date
Application number
HUE17726487A
Other languages
English (en)
Hungarian (hu)
Inventor
Jean-Christophe Andrez
Kristen Nicole Burford
Sultan Chowdhury
Charles Jay Cohen
Christoph Martin Dehnhardt
Robert Joseph Devita
James Roy Empfield
Thilo Focken
Michael Edward Grimwood
Syed Abid Hasan
James Philip Johnson Jr
Alla Yurevna Zenova
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of HUE071358T2 publication Critical patent/HUE071358T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE17726487A 2016-05-20 2017-05-19 Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk HUE071358T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339773P 2016-05-20 2016-05-20
US201662432152P 2016-12-09 2016-12-09

Publications (1)

Publication Number Publication Date
HUE071358T2 true HUE071358T2 (hu) 2025-08-28

Family

ID=58794232

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17726487A HUE071358T2 (hu) 2016-05-20 2017-05-19 Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk

Country Status (23)

Country Link
US (4) US10246453B2 (enExample)
EP (1) EP3458449B1 (enExample)
JP (4) JP6938545B2 (enExample)
KR (1) KR102366077B1 (enExample)
CN (1) CN109526219B (enExample)
AU (2) AU2017268006B2 (enExample)
CA (1) CA3023465C (enExample)
CL (1) CL2018003260A1 (enExample)
CO (1) CO2018012485A2 (enExample)
ES (1) ES3022639T3 (enExample)
HR (1) HRP20250505T1 (enExample)
HU (1) HUE071358T2 (enExample)
IL (1) IL262834B (enExample)
MX (1) MX386471B (enExample)
MY (1) MY199208A (enExample)
PH (1) PH12018502378B1 (enExample)
PL (1) PL3458449T3 (enExample)
RS (1) RS66796B1 (enExample)
RU (1) RU2769827C2 (enExample)
SG (2) SG11201809702SA (enExample)
TN (1) TN2018000385A1 (enExample)
WO (1) WO2017201468A1 (enExample)
ZA (1) ZA201807518B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458449B1 (en) 2016-05-20 2025-03-05 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
AU2017371674B2 (en) 2016-12-09 2021-07-22 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
UA127024C2 (uk) * 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
BR112021000209A2 (pt) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos
MA53488A (fr) * 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CN119118894A (zh) * 2019-11-21 2024-12-13 犹他大学研究基金会 Trpv4受体配体
WO2022077094A1 (en) * 2020-10-13 2022-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels
EP4228654A4 (en) * 2020-10-13 2024-10-16 Xenon Pharmaceuticals Inc. USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER, (S)-4-((1-BENZYLPYRROLIDIN-3-YL))(METHYL) AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL) BENZENESULFONAMIDE, IN CONJUNCTION WITH STRONG CYTOCHROME P450 3A4 INDUCERS, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAV1.6 ACTIVITY
WO2023235734A1 (en) 2022-06-02 2023-12-07 Neurocrine Biosciences, Inc. Deuterated compounds
AU2024296422A1 (en) * 2023-07-07 2025-12-18 Novartis Ag Sodium channel blockers
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
WO2025132758A1 (en) 2023-12-21 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
ES2187024T3 (es) 1997-05-07 2003-05-16 Galen Chemicals Ltd Dispositivo intravaginales de liberacion de farmacos para la adimistracion testosterona y de precursores de testosterona.
BR9916885A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
EP1202724B1 (en) 1999-07-16 2003-10-01 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
PL215132B1 (pl) 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005005421A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
JP2007501804A (ja) 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
KR20080053931A (ko) 2005-10-06 2008-06-16 사노피-아벤티스 4-옥시-ｎ-[1,3,4]-티아디아졸-2-일-벤젠 설폰아미드, 이의제조방법 및 약제로서의 이의 용도
CA2633653A1 (en) * 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
AU2007286344A1 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
EP2078018B1 (en) 2006-10-19 2012-03-14 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
JP5463285B2 (ja) 2007-07-13 2014-04-09 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
MY157017A (en) 2009-01-12 2016-04-15 Pfizer Ltd Sulfonamide derivatives
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
RU2563644C2 (ru) 2010-08-20 2015-09-20 Хатчисон Медифарма Лимитед Пирролопиримидиновые соединения и их применения
JP2014521749A (ja) 2011-08-17 2014-08-28 アムジエン・インコーポレーテツド ヘテロアリールナトリウムチャネル阻害剤
CN103889419A (zh) 2011-10-28 2014-06-25 默沙东公司 在电压门控钠离子通道中具有选择性活性的苯并噁唑啉酮化合物
JP6014155B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
KR20140091022A (ko) * 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
PE20150400A1 (es) * 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
US9376429B2 (en) 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
BR112015008987A2 (pt) 2012-10-26 2017-07-04 Merck Sharp & Dohme composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
AU2013334663A1 (en) 2012-10-26 2015-05-07 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
CN105705501B (zh) 2013-09-09 2019-04-19 百时美施贵宝公司 RORγ调节剂
US20160221974A1 (en) 2013-09-10 2016-08-04 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CN105793238B (zh) * 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
CA2934473C (en) 2013-12-23 2019-08-20 Purdue Pharma L.P. Indazoles and use thereof
EP3166939B1 (en) * 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
BR112018012408A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica?
EP3458449B1 (en) 2016-05-20 2025-03-05 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US10968210B2 (en) 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
AU2017371674B2 (en) 2016-12-09 2021-07-22 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
UA127024C2 (uk) * 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques

Also Published As

Publication number Publication date
JP2025105687A (ja) 2025-07-10
JP2023108032A (ja) 2023-08-03
CL2018003260A1 (es) 2019-01-11
ES3022639T3 (en) 2025-05-28
RS66796B1 (sr) 2025-06-30
ZA201807518B (en) 2023-07-26
CN109526219A (zh) 2019-03-26
US10815229B1 (en) 2020-10-27
CA3023465A1 (en) 2017-11-23
SG11201809702SA (en) 2018-12-28
JP2021185189A (ja) 2021-12-09
SG10201912216VA (en) 2020-02-27
AU2017268006A8 (en) 2018-12-06
US20190194184A1 (en) 2019-06-27
RU2018145045A (ru) 2020-06-22
AU2017268006A1 (en) 2018-11-22
US10246453B2 (en) 2019-04-02
AU2021203771A1 (en) 2021-07-08
US20200354354A1 (en) 2020-11-12
CN109526219B (zh) 2021-03-12
BR112018073849A2 (pt) 2019-02-26
EP3458449A1 (en) 2019-03-27
EP3458449B1 (en) 2025-03-05
MY199208A (en) 2023-10-19
JP2019516737A (ja) 2019-06-20
RU2769827C2 (ru) 2022-04-06
KR20190007050A (ko) 2019-01-21
EP3458449C0 (en) 2025-03-05
US20170334902A1 (en) 2017-11-23
CO2018012485A2 (es) 2019-04-30
MX2018013985A (es) 2019-08-22
RU2018145045A3 (enExample) 2020-06-22
MX386471B (es) 2025-03-18
WO2017201468A1 (en) 2017-11-23
PH12018502378A1 (en) 2019-03-11
CA3023465C (en) 2024-09-24
TN2018000385A1 (en) 2020-06-15
US11299490B2 (en) 2022-04-12
AU2021203771B2 (en) 2022-09-29
PH12018502378B1 (en) 2022-08-05
US10662184B2 (en) 2020-05-26
IL262834B (en) 2022-04-01
AU2017268006B2 (en) 2021-03-11
KR102366077B1 (ko) 2022-02-21
NZ748391A (en) 2025-05-30
IL262834A (en) 2018-12-31
JP6938545B2 (ja) 2021-09-22
PL3458449T3 (pl) 2025-06-23
HRP20250505T1 (hr) 2025-06-20

Similar Documents

Publication Publication Date Title
HUE071358T2 (hu) Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
EP3463464A4 (en) ASSOCIATION TREATMENT
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
EP3513809A4 (en) MEDICAL COMPOSITION
IL267143A (en) Benzenesulfonamide compounds and their use as therapeutic agents
HUE053939T2 (hu) Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk
LT3426226T (lt) Oftalmologinė kompozicija
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
SG11202004877UA (en) Sulfonamide compounds and use thereof
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
HUE046397T2 (hu) Artemizinin vegyületek és gefirin agonisták gyógyászati alkalmazása
LT3399978T (lt) Antiproliferaciniai junginiai, jų farmacinės kompozicijos ir naudojimas
EP3424940A4 (en) Radiolabeled drug
EP3556368A4 (en) THERAPEUTIC FOR ONYCHOMYCOSIS
HUE060805T2 (hu) Piridinamin-piridon és pirimidinamin-piridon vegyületek
DK3634377T3 (da) Farmaceutisk formulering
MA45187A (fr) Combinaisons pharmaceutiques
DK3408265T3 (da) Terapeutiske forbindelser
IL278949A (en) Benzene sulfonamide compounds and their use as medicinal agents
IL262851A (en) Combination prime: boost therapy